Disease Markers / 2018 / Article / Tab 3

Review Article

The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis

Table 3

Summary of meta-analysis results.

OutcomesNo. of studiesHR/RR 95% CI value valuecStudy heterogeneity
Chi2 (χ2)dfI2, % valuec

Pre-DNA
OS113.45a3.230.00142.201076<0.00001
PFS52.37a3.94<0.00012.45400.65
CR31.45b3.770.00020.37200.83
ORR51.57b4.13<0.00016.794410.15
Post-DNA
OS52.30a2.600.0090.97400.91
PFS42.35a3.140.0022.14300.54

No.: number; HR: hazard ratio; RR: relative risk; CI: confidence interval; pre-DNA: pretreatment EBV-DNA; post-DNA: posttreatment EBV-DNA; OS: overall survival; PFS: progression-free survival; CR: complete response; ORR: overall response rate. aHazard ratios. bRisk ratios. cStatistically significant results are shown in bold.